Pulmonary manifestations in children with systemic lupus erythematosus

CURRENT STATUS: UNDER REVIEW

Wujun Jiang
Soochow University Affiliated Children's Hospital

Ge Dai
Soochow University Affiliated Children's Hospital

Corresponding Author
1565312253@qq.com

Ting Wang
Soochow University Affiliated Children's Hospital

Jie Ma
Soochow University Affiliated Children's Hospital

Canhong Zhu
Soochow University Affiliated Children's Hospital

Yongdong Yan
Soochow University Affiliated Children's Hospital

Zhengrong Chen
Soochow University Affiliated Children's Hospital

DOI:
10.21203/rs.3.rs-16536/v1

SUBJECT AREAS
Rheumatology Pediatrics

KEYWORDS
systemic lupus erythematosus; pulmonary involvement; risk factors
Abstract

Background Symptomatic pulmonary involvement in systemic lupus erythematosus (SLE) is commonly reported in children. However, few studies have assessed risk factors that predict pulmonary involvement in SLE. Methods This was a seven-year retrospective study involving 111 SLE patients. The demographic, clinical and laboratory data of the patients were collected. Logistic regression analysis was performed to identify different clinical characteristics and laboratory parameters associated with presence of high resolution computerized tomography (HRCT) chest abnormalities. Results Of the 111 patients with SLE, we identified 18 patients (16.2%) with pulmonary involvement. The most common HRCT findings were ground glass opacity, interlobular septal thickening, bilateral diffuse infiltrates and pleurisy/pleural effusion (55.6%, 50%, 50%, and 44.4%, respectively). The variables independently associated with pulmonary involvement were anti-ribonucleoprotein (RNP) antibody (OR: 7.9; 95% CI: 1.1-54.6) and anti-neutrophil cytoplasmic antibodies (ANCA, OR: 73.6; 95% CI: 2.9-1894.7). Conclusions Lung involvement was frequent in SLE patients from Southeast China. Anti-RNP antibody and ANCA were significantly associated with abnormal HRCT findings.

Background

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown etiology in which tissues and cells are damaged by pathogenic autoantibodies and immune complexes. Adult SLE and childhood SLE have similar clinical features, but children are known to have a more severe disease course. SLE is the most common connective tissue disease affecting the lung, with a similar proportion between adults and children. In children with SLE, it has been reported that pulmonary involvement occurred in 7.6–75% of the patients\textsuperscript{1–3}. The types of pulmonary manifestations reported involve any portion of
the pulmonary organ system including the pleura, diaphragm, parenchyma, and vasculature.

Due to the potentially high prevalence of lung complications in SLE, assessing the risk factors that predict pulmonary manifestations is of great importance. It was reported that SLE duration, low complement levels, high anti-dsDNA levels and disease activity were the risk factor associated with the development of pulmonary manifestations in adult patients\textsuperscript{4, 5}. Nevertheless, no studies have assessed the risk factors that predict pulmonary manifestations in children with SLE.

Therefore, in this study, we retrospectively investigated the prevalence of pulmonary manifestations in childhood SLE in order to determine risk factors for developing lung abnormalities.

Method

Patients and study design

This was a hospital-based study conducted at Children’s Hospital of Soochow University located in the Southeast region of China. We performed a retrospective review of the records of patients diagnosed with SLE from 1 January 2012 to 31 December 2016. They were followed consecutively either as inpatients or outpatients until December 2019. We enrolled patients aged < 18 years who were diagnosed with SLE under the Criteria of the American Rheumatism Association for a diagnosis of SLE\textsuperscript{6}. Patients with mixed connective tissue diseases were excluded from the study. This investigation was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Research Committee of Children’s Hospital of Soochow University.

Data collection

The demographic and clinical data of patients with SLE including patients’ age at onset,
gender, disease duration (calculated from symptoms onset to the end of the study), follow-up duration, different clinical features at presentation. Laboratory data collected included hematological and immunological parameters consisting of the lowest levels of complement components 3 and 4 (C3 and C4) (low C3:<90 mg/dl; low C4:<20 mg/dl), anti-double stranded (ds) DNA antibody, anti-Smith (Sm) antibody, anti-neutrophil cytoplasmic antibodies (ANCA), anti-ribonucleoprotein (RNP) antibody, anti-SSA antibody and anti-SSB antibody.

Two senior radiologists independently reviewed HRCT scans, with each diagnosis reached by consensus. Furthermore, the presence of the following pulmonary HRCT manifestations was recorded as previously described\textsuperscript{7, 8}: pleurisy/pleural effusion, pneumonitis, interstitial lung disease, bronchiectasis, diffuse alveolar hemorrhage and pulmonary edema. Respiratory involvement was considered primary when it was directly related to SLE activity, and infections, drug toxicity, and neoplasia had been excluded.

**Statistical analysis**

We used n (%) for categorical variables and median (quartiles) for continuous variables with non-normal distribution or mean and standard deviation (SD) for those with normal distribution. We assessed differences in categorical variables with the $\chi^2$ test or Fisher exact test. We calculated 95% confidence interval (95% CI) for differences in medians with an exact test. Logistic regression analysis was performed to identify different clinical characteristics and laboratory parameters associated with presence of HRCT chest abnormalities. SPSS (version 22.0) software was used for all statistical analysis.

**Results**

A total of 111 SLE patients were included in our study. Of these, 73.0% were female and 27.0% were male; median age at SLE diagnosis was 136 (range 108 ~ 156) months. Median
period of follow-up was 36 months (range, 1–84 months). The presenting symptoms at
diagnosis are summarized in Table 1. Cutaneous lesions (71.2%), fever (56.8%), nephritis
(56.8%) and hematological involvement (51.4%) were the major clinical manifestations. Of
the 111 SLE patients, pulmonary involvement was found in 18 (16.2%) patients, yielding
an overall prevalence of 16.2% (95% CI: 9.3–23.2).

Table 1
Demographic and clinical characteristics of systemic lupus erythematosus (SLE) patients in this study
(n = 111)

| Demographic characteristics                  | Patients (n (%) |
|-----------------------------------------------|----------------|
| Demographic characteristics                  |                |
| Female/male                                   | 1:0.37         |
| Age at SLE diagnosis, median (range), m       | 136 (108–156)  |
| Clinical characteristics, n (%)               |                |
| Fever                                         | 63 (56.8)      |
| Cutaneous                                     | 79 (71.2)      |
| Arthritis                                     | 22 (19.8)      |
| Mucosal lesion                                | 20 (18.0)      |
| Nephritis                                     | 63 (56.8)      |
| Pulmonary involvement                         | 18 (16.2)      |
| Pericarditis                                  | 18 (16.2)      |
| Gastrointestinal involvement, except hepatitis| 14 (12.6)      |
| Hepatitis                                     | 14 (12.6)      |
| Hematologic abnormalities                     | 57 (51.4)      |
| Neuropsychiatric manifestations               | 11 (9.9)       |

Data concerning HRCT scans of the SLE patients with pulmonary involvement are
presented in Table 2. Ground glass opacity was found in 10 (55.6%) patients, interlobular
septal thickening in 9 (50.0%) patients, bilateral diffuse infiltrates in 9 (50.0%) patients,
pleurisy/pleural effusion in 8 (44.4%) patients, fibrotic streak in 6 (33.3%) patients and
patchy infiltrates in 5 (27.8%) patients (Fig. 2). Most of the abnormalities were distributed
bilaterally (94.4%), in the lower lobes (82.3%) or subpleural regions (61.1%).
Table 2
Summary of HRCT findings in SLE patients showing pulmonary involvement

| HRCT findings                     | N (%) *          |
|----------------------------------|------------------|
| Abnormalities                    |                  |
| Ground glass opacity             | 10 (55.6)        |
| Interlobular septal thickening   | 9 (50.0)         |
| Bilateral diffuse infiltrates    | 9 (50.0)         |
| Pleurisy/pleural effusion        | 8 (44.4)         |
| Fibrotic streak                  | 6 (33.3)         |
| Patchy infiltrates               | 5 (27.8)         |

| Distribution of abnormalities    |                  |
|----------------------------------|------------------|
| Bilateral                        | 17 (94.4)        |
| Lower lobes                      | 14 (82.3)        |
| Subpleural regions               | 11 (61.1)        |
| Patchy random distributed        | 4 (22.2)         |

*Multiple abnormalities were present in each patient.

In the univariate analysis, SLE patients with pulmonary involvement were more likely to be presented with pericarditis and neuropsychiatric manifestations (both P < 0.05). We also observed a significant association between the presence of anti-Sm antibody, ANCA, Anti-RNP and the presence of pulmonary involvement of SLE (all P < 0.001; Table 3). In the multivariate analysis, the variables independently associated with pulmonary involvement were and ANCA and anti-RNP antibody. The odds of pulmonary involvement among infants with positive anti-RNP antibody were significantly greater than among those with negative anti-RNP antibody (OR: 7.9; 95% CI: 1.1–54.6), as were the odds of pulmonary involvement among infants with positive ANCA compared with those with negative ANCA (OR: 73.6; 95% CI: 2.9-1894.7).
Table 3
Demographic, clinical and laboratory data of systemic lupus erythematosus (SLE) patients with and without pulmonary involvement (n = 111)

| Demographic characteristics | Pulmonary involvement (n = 18) | No pulmonary involvement (n = 93) | P value |
|-----------------------------|-------------------------------|----------------------------------|---------|
| Gender                      | 1:0.29                        | 1:0.39                           | 0.77    |
| Age at SLE diagnosis, median (quartile), m | 136.50 (121–147) | 136 (92–156) | 0.75    |
| Clinical characteristics, n (%) |                               |                                  |         |
| Fever                       | 11 (61.1)                     | 52 (55.9)                        | 0.80    |
| Cutaneous                   | 13 (72.2)                     | 66 (71.0)                        | 0.98    |
| Arthritis                   | 6 (33.3)                      | 16 (17.2)                        | 0.19    |
| Mucosal lesion              | 5 (27.8)                      | 15 (16.1)                        | 0.31    |
| Nephritis                   | 14 (77.8)                     | 49 (52.7)                        | 0.07    |
| Pericarditis                | 10 (55.6)                     | 8 (8.6)                          | <0.001  |
| Gastrointestinal involvement, except hepatitis | 3 (16.7)                     | 11 (11.8)                        | 0.70    |
| Hepatitis                   | 4 (22.2)                      | 10 (10.8)                        | 0.24    |
| Hematologic abnormalities   | 12 (66.7)                     | 45 (48.4)                        | 0.20    |
| Neuropsychiatric manifestations | 5 (27.8)                     | 6 (6.5)                          | 0.02    |
| Low complement 3 level      | 16 (88.9)                     | 58 (62.4)                        | 0.03    |
| Low complement 4 level      | 16 (88.9)                     | 66 (71.0)                        | 0.15    |
| Anti-dsDNA antibody positivity | 16 (88.9)                     | 82 (88.2)                        | 1.00    |
| Anti-Sm antibody positivity | 11 (61.1)                     | 14 (15.1)                        | <0.001  |
| Anti-Ro antibody positivity | 7 (38.9)                      | 41 (44.1)                        | 0.80    |
| ANCA positivity             | 16 (88.9)                     | 17 (18.3)                        | <0.001  |
| Anti-RNP antibody positivity | 12 (66.7)                     | 15 (16.1)                        | <0.001  |
| Anti-SSB antibody positivity | 5 (27.8)                      | 18 (19.4)                        | 0.53    |

Discussion

In the present study, we have determined the prevalence of pulmonary involvement in SLE to be 16.2% in the Southeast region of China. The frequency of symptomatic pulmonary involvement at diagnosis in children with SLE ranges from 7.6% to 75%\textsuperscript{1, 9, 10}. The wide range of prevalence found in the previous studies may be due to known racial and ethnic phenotypic variability, as well as different approaches taken to determine the presence of pulmonary involvement with SLE.

The types of pulmonary manifestations reported are diverse, and may involve any portion of the pulmonary organ system including the pleura, diaphragm, parenchyma, and
vasculature\(^3\). However, the most common pulmonary involvement appears to be pleuritis, which affects 12.5–32% of children with SLE during the course of their disease\(^2, 11\). In our study, pleuritis affects 7.2% (8/111) of children with SLE. Moreover, 94.4% of the children with pulmonary involvement display bilateral presentation. The high prevalence of bilateral involvement in our study is in line with the previous studies\(^1, 9, 12\).

The presence of anti-RNP antibody was described to be specific (specificity ranging from 84–100%) of mixed connective tissue disease\(^13\). Previous reports found that positive anti-RNP antibody are risk factors for pulmonary arterial hypertension in patients with SLE\(^14–16\). Anti-RNP positivity is also reported to be associated with a more frequent pulmonary involvement in other connective tissue disease\(^17\). Our results are the first study that emphasize the role of anti-RNP positivity in predicting occurrence of pulmonary involvement in childhood SLE.

In our study, ANCA positivity was also independently associated with pulmonary involvement in children with SLE. ANCA is a group of autoantibodies against specific antigens such as neutrophil cytoplasmic granules and monocyte lysosomes. The discovery of ANCA helped establish ANCA-associated vasculitis as a separate and well-defined clinical entity\(^18, 19\). Previous studies reported that the positive rate of ANCA in patients with SLE ranges from 25–69\(^{\%}\)\(^20–22\). In our study, 33 of the 111 SLE children were positive for ANCA, with a positive rate of 29.7\(^{\%}\), which was consistent with the previous reports. The relationship between positive ANCA and pulmonary involvement has also reported in previous studies, especially in adult patients\(^20, 22\). Therefore, when the children with SLE is found to have positive ANCA, it should be alert to the occurrence of pulmonary involvement.
Our study has some limitations. First, it is a retrospective study. It is possible that some patient information could have been missed despite efforts by the authors to record all pertinent details. Second, the data which were collected from a single center may have introduced bias. Third, the total number excluded in our study is relatively small. Thus, a multicenter, prospective study is warranted to evaluate pulmonary manifestations in children with SLE.

Conclusions

In conclusion, lung involvement was frequent in SLE patients from Southeast China. Anti-RNP antibody and ANCA were significantly associated with abnormal HRCT findings.

List Of Abbreviations

SLE  systemic lupus erythematosus
HRCT  high resolution computerized tomography
RNP  ribonucleoprotein
ANCA  anti-neutrophil cytoplasmic antibodies
SD  standard deviation

Declarations

Ethics approval and consent to participate

This investigation was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Research Committee of Children’s Hospital of Soochow University.

Consent for publication

Not applicable.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.
Competing interests
The authors declare that they have no competing interests.

Funding
This project has been funded by the Special funding for diagnosis and treatment of key clinical diseases in Suzhou(NO:LCZX201809)and National Natural Science Foundation of China(NO:81870006).

Authors' contributions
YDY and ZRC conceived the idea and supervise the project, JM collected patient samples and data.CHZ contributed to the design of the study and analysis of the literature.WJJ, GD and TW wrote the manuscript.All authors read and approved the final manuscript.

Acknowledgements
None.

Authors' information
1 Children’s Hospital of Soochow University, Suzhou, China.

References
1. Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr 1999;135:500-5.
2. Lilleby V, Aalokken TM, Johansen B, Forre O. Pulmonary involvement in patients with childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2006;24:203-8.
3. Huggins JL, Holland MJ, Brunner HI. Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus 2016;25:857-63.
4. Alamoudi OS, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: Association with disease activity. Respirology 2015;20:474-80.
5. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007;28:441-50.
6. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.

7. Quadrelli SA, Alvarez C, Arce SC, Paz L, Sarano J, Sobrino EM, Manni J. Pulmonary involvement of systemic lupus erythematosus: Analysis of 90 necropsies. Lupus 2009;18:1053-60.

8. Mayberry JP, Primack SL, Muller NL. Thoracic manifestations of systemic autoimmune diseases: Radiographic and high-resolution ct findings. Radiographics 2000;20:1623-35.

9. Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in sultanate of oman: Demographics and clinical analysis. Lupus 2008;17:683-6.

10. Beresford MW, Cleary AG, Sills JA, Couriel J, Davidson JE. Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus 2005;14:152-8.

11. Delgado EA, Malleson PN, Pirie GE, Petty RE. The pulmonary manifestations of childhood onset systemic lupus erythematosus. Semin Arthritis Rheum 1990;19:285-93.

12. Blay G, Rodrigues JC, Ferreira JCO, Leal GN, Gormezano NW, Novak GV, Pereira RMR, et al. Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: A severe disease flare with serious outcome. Adv Rheumatol 2018;58:39.

13. Benito-Garcia E, Schur PH, Lahita R, American College of Rheumatology Ad Hoc Committee on Immunologic Testing G. Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-sm and anti-rnp antibody tests. Arthritis Rheum 2004;51:1030-44.

14. Wang J, Qian J, Wang Y, Zhao J, Wang Q, Tian Z, Li M, et al. Serological biomarkers as
risk factors of sle-associated pulmonary arterial hypertension: A systematic review and meta-analysis. Lupus 2017;26:1390-400.

15. Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J, Lai J, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine (Baltimore) 2016;95:e2761.

16. Kim JS, Kim D, Joo YB, Won S, Lee J, Shin J, Bae SC. Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus 2018;27:1769-77.

17. Abbara S, Seror R, Henry J, Chretien P, Gleizes A, Hacein-Bey-Abina S, Mariette X, et al. Anti-rnp positivity in primary sjogren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. RMD Open 2019;5:e001033.

18. Allard-Chamard H, Liang P. Antineutrophil cytoplasmic antibodies testing and interpretation. Clin Lab Med 2019;39:539-52.

19. Sinico RA, Radice A. Antineutrophil cytoplasmic antibodies (anca) testing: Detection methods and clinical application. Clin Exp Rheumatol 2014;32:S112-7.

20. Su F, Xiao W, Yang P, Chen Q, Sun X, Li T. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. An Bras Dermatol 2017;92:466-9.

21. Sobral S, Ramassur K, Apsley E, Isenberg D. Do anti-neutrophil cytoplasmic antibodies play a role in systemic lupus erythematosus (sle) patients? Analysis of the university college hospital sle cohort. Lupus 2018;27:343-4.

22. Manolova I, Dancheva M, Halacheva K. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: Prevalence, antigen specificity, and clinical associations. Rheumatol Int 2001;20:197-204.

Figures
**Figure 1**

HRCT scans of the SLE patients with pulmonary involvement. (A) Fibrotic streak; (B) Reticular pattern; (C) Mosaic perfusion; (D) Pleural thickening (E) Ground glass opacity; (F) Subpleural interlobular septal thickening.